Wall Street Journal - Biogen’s stock got hammered earlier this month when old safety worries resurfaced for the company’s multiple sclerosis drug Tysabri. For Carl Icahn, it was a buying opportunity.
Wall Street Journal - Biogen’s stock got hammered earlier this month when old safety worries resurfaced for the company’s multiple sclerosis drug Tysabri. For Carl Icahn, it was a buying opportunity.
